MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

7.58
-0.18
-2.32%
After Hours: 7.50 -0.08 -1.06% 19:30 04/13 EDT
OPEN
7.77
PREV CLOSE
7.76
HIGH
7.87
LOW
7.52
VOLUME
460.97K
TURNOVER
--
52 WEEK HIGH
19.47
52 WEEK LOW
4.710
MARKET CAP
145.88M
P/E (TTM)
-3.5259
1D
5D
1M
3M
1Y
5Y
Relapsed Acute Myeloid Leukemia Drug Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2027
Apr 08, 2021 (Market Insight Reports) -- The latest report as Relapsed Acute Myeloid Leukemia Drug Market acknowledges Size, Application Segment, Type,...
Market Insight Reports · 5d ago
Global Hodgkin's Lymphoma Treatment Market Size, Outlook 2021 | Industry Statistics, Emerging Technologies, Business Challenges, Covid-19 Outbreak, Explosive Factors of Revenue Expansion and Strategies 2026
Apr 07, 2021 (The Expresswire) -- Global Hodgkin's Lymphoma Treatment Market Research Report 2021: The Global Hodgkin's Lymphoma Treatment Market report...
The Express Wire · 6d ago
Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
The following article is sponsored by Actinium Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
Benzinga · 04/06 13:07
Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 04/05 06:23
DJ Actinium Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/01 10:53
DJ Actinium Pharmaceuticals Price Target Cut to $57.00/Share From $65.00 by HC Wainwright & Co.
Dow Jones · 04/01 10:53
Actinium to Participate in the Cell & Gene Meeting on the Mediterranean
PR Newswire · 03/31 23:11
10-K: ACTINIUM PHARMACEUTICALS, INC.
Edgar Online - (EDG = 10Q, 10K) · 03/31 21:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNM. Analyze the recent business situations of ACTINIUM PHARMAC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATNM stock price target is 36.75 with a high estimate of 57.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 23.40M
% Owned: 121.57%
Shares Outstanding: 19.25M
TypeInstitutionsShares
Increased
10
5.54M
New
5
10.91M
Decreased
6
1.59M
Sold Out
5
306.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer/Chief Accounting Officer
Steve O'Loughlin
Chief Scientific Officer
Dale Ludwig
Other
Mark Berger
Vice President
Robert Daly
Lead Director/Independent Director
C. David Nicholson
Vice President
Steven Price
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Vice President
Vijay Reddy
Independent Director
Richard Steinhart
Vice President
Jehan Rowlands
Independent Director
C.David Nicholson
Independent Director
C. Nicholson
No Data
  • All
  • Financials
  • Insiders
More
About ATNM
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.